Table 20Summary of strength of evidence of efficacy, by drug and condition

– generalized anxiety disorder-++--
– social phobia+-
Attention Deficit/Hyperactivity Disorder
-no co-occurring disorders+
Attention Deficit/Hyperactivity Disorder
-bipolar children-
Attention Deficit/Hyperactivity Disorder
-mentally retarded children+
Dementia overall++++++
Dementia psychosis++-+-++
Dementia agitation++++-++
-MDD augmentation of SSRI / SNRI Image resultsfu1.jpg Image resultsfu2.jpg Image resultsfu3.jpg+++
-MDD: Monotherapy-++
Eating Disorders---
Obsessive Compulsive Disorder
-augmentation of SSRI+--++-
Obsessive Compulsive Disorder
-augmentation of citalopram++
Personality Disorder
Personality Disorder
Post Traumatic Stress Disorder+-+++
Substance Abuse alcohol----
Substance Abuse cocaine--
Substance Abuse methamphetamine-
Substance Abuse methadone clients-
Tourette's Syndrome+-

Image resultsfu4.jpg moderate or high evidence of efficacy

Image resultsfu5.jpg low or very low evidence of efficacy

Image resultsfu6.jpg mixed results

Image resultsfu7.jpg low or very low evidence of inefficacy

Image resultsfu8.jpgmoderate or high evidence of inefficacy

○ : no trials

Image resultsfu9.jpg: Approved by FDA for the indication

MDD = major depressive disorder; SNRI = serotonin-norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor

Note: Symbols denote strength of evidence, not size of potential effect. For example in dementia “++” indicates moderate-to-high strength of evidence that there is a beneficial effect, however the size of the effect is small.

From: Results

Cover of Off-Label Use of Atypical Antipsychotics: An Update
Off-Label Use of Atypical Antipsychotics: An Update [Internet].
Comparative Effectiveness Reviews, No. 43.
Maglione M, Maher AR, Hu J, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.